Compare BH & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | FTRE |
|---|---|---|
| Founded | 1934 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | BH | FTRE |
|---|---|---|
| Price | $386.32 | $16.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 70.8K | ★ 1.3M |
| Earning Date | 11-07-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.91 | N/A |
| Revenue | $386,507,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.21 |
| Revenue Next Year | N/A | $0.25 |
| P/E Ratio | $559.13 | ★ N/A |
| Revenue Growth | ★ 6.87 | 1.88 |
| 52 Week Low | $195.05 | $3.97 |
| 52 Week High | $483.60 | $18.67 |
| Indicator | BH | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 51.55 |
| Support Level | $365.35 | $16.09 |
| Resistance Level | $408.87 | $17.41 |
| Average True Range (ATR) | 25.86 | 1.09 |
| MACD | -11.75 | -0.14 |
| Stochastic Oscillator | 8.71 | 43.38 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.